Novo Nordisk is initiating a new Phase 3 clinical trial, named REDEFINE 11, to further investigate the potential of its next-generation obesity drug, CagriSema. This trial is part of the broader REDEFINE program and will focus on optimizing dosing strategies through dose escalation and re-escalation, as well as extending the trial duration beyond previous studies. The study aims to explore whether these adjustments can achieve greater weight loss outcomes than observed in earlier trials, such as REDEFINE 1 and REDEFINE 2
The trial is expected to begin in the first half of 2025, with results anticipated before the planned submission for regulatory approval in early 2026
Discover how we can elevate your portfolio and deliver exceptional growth. NEW Monthly Payout Of At Least 0.5% In US Dollars
AlgoTrader 